The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II/ III trial of nivolumab versus nivolumab plus docetaxel for previously treated advanced or recurrent non–small cell lung cancer: TORG1630.
 
Yosuke Kawashima
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Taiho Pharmaceutical
 
Yuri Taniguchi
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Taiho Pharmaceutical (Inst)
 
Tsuneo Shimokawa
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Taiho Pharmaceutical (Inst)
 
Yuichi Takiguchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; MSD Oncology; Taiho Pharmaceutical
 
Toshihiro Misumi
No Relationships to Disclose
 
Atsushi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Kirin; Lilly Japan; Novartis; Taiho Pharmaceutical; Thermo Fisher Scientific
 
Naoki Furuya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
 
Kentaro Tanaka
Honoraria - AstraZeneca; Bristol-Myers Squibb/Ono Pharmaceutical; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck; MSD; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Janssen
Research Funding - AstraZeneca/MedImmune (Inst); Chugai Pharma; Daiichi Sankyo/UCB Japan
 
Toshiyuki Harada
No Relationships to Disclose
 
Hisashi Tanaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Pfizer
 
Satoru Miura
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Merck KGaA; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Masafumi Sata
Speakers' Bureau - Daiichi Sankyo/UCB Japan; Lilly Japan; Ono Pharmaceutical
Research Funding - Boehringer Ingelheim Seiyaku
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Lilly; Merck Serono; MSD; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Chugai Pharma (Inst); Haihe Biopharma (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)
 
Takaaki Tokito
Honoraria - Chugai Pharma; Merck; Novartis
 
Katsuhiko Naoki
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Meyers; Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst)
 
Akihiro Bessho
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); MSD K.K (Inst); Pfizer (Inst)
 
Yasuhiro Goto
Stock and Other Ownership Interests - Chugai Pharma
Speakers' Bureau - AstraZeneca Japan; Boehringer Ingelheim; Bristol Myers Squibb; Chugai Pharma; Kyowa Kirin International; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Shinji Nakamichi
Honoraria - AstraZeneca; Bristol-Myers Squibb/Ono Pharmaceutical; Chugai Pharma; Merck; Taiho Pharmaceutical; Takeda
 
Hiroaki Okamoto
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)